It has been already proved from clinical study that ibuprofen piconol cream, which is designed as an ethical drug and contains 5% of active agent, is effective on acne vulgaris. In this study we tested clinical efficacy of a newly developed proprietary drug, ibuprofen piconol cream (BO-31) which contained 3% of the active ingredient and whose vehicle was formulated in oil in water emulsion base with less amount of oil content than the ethical cream of 5% ibuprofen piconol. The subjects were 100 patients with moderate to slight degrees of acne vulgaris. The subjects used BO-31 more than 4 weeks twice a day. The results showed that 6 cases were remarkably improved, 50 cases were definitely improved, 29 cases were some improved, while 11 cases were not improved. The effective ratio more than definitely improved was 58. 3% among 96 cases which could be analysed of efficacy. Side effect was seen only in one case (1. 1%, 1/95 cases) who noticed slight itchy erythema 14 days after starting to apply BO-31. This skin manifestation subsided in 3 days since she stopped applying BO-31. The feeling of usage of BO-31 was better or rather better in 27 cases out of 40 cases who had used the other topical agents for acne vulgaris before this trial. We concluded that BO-31 is an effective and useful topical agent for acne vulgaris.
All Science Journal Classification (ASJC) codes
- Infectious Diseases